The Role of Pre-therapeutic 18F-FDG PET/CT in Pediatric Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus Infection
Open Access
- 21 January 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 836438
Abstract
Objective: To evaluate the role of pre-therapeutic 18F-FDG PET/CT in pediatric hemophagocytic lymphohistiocytosis (HLH) with Epstein-Barr virus (EBV) infection.Methods: This retrospective study included 29 HLH children (1–16 years) with EBV infection, who underwent pre-therapeutic 18F-FDG PET/CT from July 2018 to November 2020. Pathology results were considered as the reference standard. These patients were divided into two groups: EBV-induced malignancy-associated HLH (M-HLH, N = 9) and EBV-induced non-malignancy-associated HLH (NM-HLH, N = 20). The regions of interest (ROIs) of the liver, spleen (Sp), bone marrow (BM), lymph nodes (LN), hypermetabolic lesions, liver background (LiBG), and mediastinum (M) were drawn with software 3D-Slicer. The volumetric and metabolic parameters, including maximum standard uptake value (SUVmax), metabolic tumor volume, and total lesion glycolysis of these ROIs, clinical parameters, and laboratory parameters were compared between the two groups. The efficiency of the above parameters in predicting the treatment response and overall survival (OS) was analyzed.Results: Receiver operating characteristic curve analysis indicated that SUVmax-lesions and SUVmax-LN/M (AUC = 0.822, 0.819, cut-off = 6.04, 5.74, respectively) performed better in differentiating M-HLH from NM-HLH. It had the best diagnostic performance when age was added with the SUVmax-LN/M (AUC = 0.933, sensitivity = 100%, specificity = 85.0%). The presence of extranodal hypermetabolic lesions in multiple organs indicated the M-HLH (P = 0.022). Older age, higher SUVmax-LN and SUVmax-lesions, and the presence of serous effusion were associated with poorer treatment response at the 2nd and 4th week (not reaching partial remission). Multivariate analysis showed that SUVmax-lesions > 7.66 and SUVmax-Sp/LiBG > 2.01 were independent prognostic factors for overall survival (P = 0.025, 0.036, respectively).Conclusions: 18F-FDG PET/CT could be a valuable technique for identifying the underlying malignancy and predicting prognosis in pediatric HLH with EBV infection. M-HLH could be considered when SUVmax-lesions > 6.04, SUVmax-LN/M > 5.74, and the presence of extranodal hypermetabolic lesions in multiple organs on 18F-FDG PET/CT. SUVmax-lesions and SUVmax-Sp/LiBG might be independent prognostic factors for OS.Keywords
Funding Information
- National Natural Science Foundation of China (81771860, 81971642)
- Natural Science Foundation of Beijing Municipality (7192041)
- National Key Research and Development Program of China (2020YFC0122000)
- National Science and Technology Major Project (2017ZX09304029001)
- Beijing Municipal Administration of Hospitals (XTZD20180202)
This publication has 41 references indexed in Scilit:
- Interferon-gamma–mediated tissue factor expression contributes to T-cell-mediated hepatitis through induction of hypercoagulation in miceHepatology, 2012
- The significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosisJournal of Hematology & Oncology, 2012
- Acute or Chronic Life-Threatening Diseases Associated With Epstein-Barr Virus InfectionThe American Journal of the Medical Sciences, 2012
- Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumabPediatric Blood & Cancer, 2012
- Hemophagocytosis causes a consumptive anemia of inflammationJournal of Experimental Medicine, 2011
- Epstein-Barr Virus Mimicking Lymphoma on FDG-PET/CTClinical Nuclear Medicine, 2009
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006
- Proposed guidelines for diagnosing chronic active Epstein‐Barr virus infectionAmerican Journal of Hematology, 2005
- Increased serum levels of interferon-γ-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosisClinical and Experimental Immunology, 2003
- Utility of FDG-PET scanning in lymphoma by WHO classificationBlood, 2003